Morgan Stanley analyst Kristine Liwag lowered the firm’s price target on TransDigm (TDG) to $1,600 from $1,750 and keeps an Overweight rating on the shares. Defense Primes are poised to report Q3 earnings amidst one of the longest government shutdowns in history, which does not make it easy for management teams to guide to 2026 with clarity, the analyst tells investors. However, the firm would be buyers of tepid Defense outlooks as upward revisions should materialize as the funding picture clears up, adds the analyst, whose Top Pick in Defense remains Northrop Grumman (NOC).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDG:
- TransDigm price target lowered to $1,450 from $1,500 at Susquehanna
- TransDigm price target lowered to $1,370 from $1,490 at Deutsche Bank
- TransDigm initiated with an Outperform at BMO Capital
- TransDigm removed from Franchise Picks list at Jefferies
- Jefferies cuts TransDigm target, removes from Franchise Picks list